Dean, Golden Domain, Steady, Blue Sail stock prices skyrocketed! The pharmaceutical sector opens a new market!

Pharmaceutical Network January 22nd morning, A-shares ushered in a high open, and finally the Shanghai Composite Index closed at 3621.26 points, re-stationed at 3600 points this five-year capital market high, the GEM Index is up 2.24%, another nearly six-year high.
by the day before the National Health and Safety Commission asked to further strengthen the support of the new crown detection policy, the new crown detection plate rose sharply, Cape Biology, Dean Diagnostics rose by more than 10%, Jin domain medicine, Minder Biology, Xiyi Science and other popular enterprises rose and stopped, Susse Bio, Da'an gene, Huada gene and other collective rise.
the theme of epidemic prevention and control market volume according to the Ministry of Transport Department data, it is expected that the 2021 National Spring Festival travel period sent 1.7 billion passengers, an average of 40 million daily, an increase of more than 10% over 2020.
2020, the country's total nucleic acid testing 300 million, taking into account the policy to encourage local New Year and send passengers do not need to repeat nucleic acid testing, conservative estimates of the Spring Festival during the nucleic acid detection of 170 million people.
In response to the outbreak control during the Spring Festival, the State Council to deal with the new coronavirus pneumonia outbreak joint prevention and control mechanism integrated group and the Central Rural Work Leading Group Office formulated the "winter and spring rural areas new crown pneumonia epidemic prevention and control work programme" pointed out that returnees need to hold 7 days effective neovirus nucleic acid test negative results return home, return home after 14 days of home health monitoring, during which no gathering, non-flow, every 7 days to carry out a nuclear acid test.
Industry insiders pointed out that from the product point of view, the outbreak prevention and control stage for the demand for new crown diagnostic reagents is rigid, and independent medical examination (ICL) charge a single price of more than 70 yuan, some cities even more than 100 yuan, the comprehensive strengthening of the new crown detection for the relevant enterprises will bring real performance.
Recently, nucleic acid testing reagents related listed companies have also issued the 2020 annual performance advance announcement, Wantay Bio 2020 net profit increased by 215% to 244%, the performance growth is due to the new product two-price cervical cancer vaccine on the market sales, and the introduction of a new coronary pneumonia testing reagent.
, Cap Bio, Minder Bio, Mike Bio, Wanfu Bio and other companies have announced pre-increases, including domestic and foreign markets for new crown testing products increased demand.
to strengthen the prevention and control of the epidemic further led to the overall medical and health sector volume increased.
the close of trading, including blond technology, blue sail medical, British medical, health care and other related products, including masks, protective clothing, gloves and other related products production and supply enterprises, the stock price performance is very eye-catching.
Three-medical linkage" pattern has been popular in fact, not only with the increase in demand for epidemic prevention and control related to protective supplies, new crown testing, service institutions theme by the capital market hot, into 2021, the capital market pharmaceutical sector continued to be active, by the "three-doctor linkage" "health insurance negotiations" "two-set plan" and many other policies to promote, innovative drugs, retail chains, research and development and production services (CXO) and other topics by the capital market.
On January 12, the State Administration of Medical Security announced the Interim Measures for the Administration of Fixed-Point Medical Security in Medical Institutions and the Interim Measures for the Fixed-Point Management of Medical Security in Retail Pharmacies, which stipulate that eligible medical institutions and retail pharmacies may be included in the fixed-point management of medical insurance by applying for a medical insurance agreement, and have clarified the basic conditions and procedures for the signing of the agreement.
After, the capital market pharmaceutical retail sector collective jumped sharply, as of the end of the day, the people, Dasinlin, Yifeng pharmacy and Jianjia closed the board, a heart-to-heart surge of 7.49%, and since then opened a week of sustained gains.
January 15, the executive meeting of the State Council deployed to further promote the reform of drug centralized belt procurement, with normal institutional measures to reduce the burden of medical treatment for the masses, at the same time, the meeting proposed that collection should take into account the reasonable profits of enterprises, promote product innovation and upgrading, to save medical insurance costs in accordance with the provisions to give medical institutions residual incentives, and strive to make this reform to achieve patients and enterprises, medical institutions benefit.
"Promoting product innovation and upgrading" was encouraged by the top-level policy, coupled with the capital market for Zhao Yanxin Pharmaceuticals, Pharmaceutical Mingkang, Tag Pharmaceuticals, Boji Pharmaceuticals, Kailaiying, Kanglonghuacheng and many other CRO, CDMO enterprises 2020 annual report expectations of a high degree of optimism, corporate share prices ushered in a collective rise.
CXO's shares rose more than 10 per cent in the five trading days to the close of trading on January 21.
January 20, the pharmaceutical and biological sector still led the rise, as of the close, Opcon TV, Innovative Medical, Kyusju Pharmaceuticals, Asia Pacific Pharmaceuticals and other stocks rose and stopped, Kanglonghua into a rise of more than 13%, Kantai Bio, a mammoth and other enterprises followed.
as a capital market concentration of innovative biopharmaceutical enterprises, the Hong Kong stock market has also embarked on the capital wind in recent days.
Consecutive trading days, Baiji Shenzhou, Junshi Bio, Kangfang Bio, Sonic Pharmaceuticals, Yunding Xinyao, Fuhong Hanxuan, Hansen Pharmaceuticals, Geli Pharmaceuticals and other companies rose strongly, of which the shares of Reding Pharmaceuticals in just a few trading days has quickly set foot on the 1500 yuan mark.
Industry analysis that the global epidemic prevention and control situation can not be ignored, medical services, pharmaceutical equipment and life science and technology industry will continue to become the focus of attention in the capital market, "three medical linkage" reform continues to deepen, the pharmaceutical industry is facing the initial pain and shuffle basic completion, innovation has become the core competitiveness of enterprise development.